Respiri (ASX:RSH) shares have been up as much as 23 per cent in early trade after TerryWhite Chemmart agreed to sell and market its wheezo asthma-management device in its pharmacies.

TerryWhite has over 450 community pharmacies, Respiri said. The agreement takes the number of pharmacies contracted to sell and stock wheezo to about 1,000 Australian stores.

“Respiri continues to grow wheezo product availability in the pharmacy channel as we recognise the important role that pharmacies play with supporting asthma management and care,” chief executive Marjan Mikel said.

Respiri is in active discussions with several other large pharmacy banner groups, Mikel said.

Respiri began selling the smartphone-connected wheeze-detecting devices in Australia in October, with a UK launch planned for later this year and the US in third quarter of 2022.

At 11.47am, Respiri shares were up 9.1 per cent to 12c. They had traded as high as 13.5c earlier this morning.